

**POLICY:** Oncology (Injectable) – Tivdak

- Tivdak™ (tisotumab vedotin-tftv intravenous infusion – Seagen and Genmab)

**EFFECTIVE DATE:** 02/01/2022

**REVIEW DATE:** 09/16/2024

**COVERAGE CRITERIA FOR:** All Aspirus Medicare Plans

---

### **OVERVIEW**

Tivdak, a tissue factor-directed antibody and microtubule inhibitor conjugate, is indicated for the treatment of adults with recurrent or metastatic **cervical cancer** with disease progression on or after chemotherapy.<sup>1</sup>

### **Dosing Information**

The recommended dose of Tivdak is 2 mg/kg (to a maximum of 200 mg for patients weighing ≥ 100 kg) administered by intravenous infusion over 30 minutes once every 3 weeks until disease progression or unacceptable adverse events.<sup>1</sup> Ophthalmic exams, including visual acuity and slit lamp exam, should be conducted at baseline, prior to each dose, and as needed. Patients should receive topical corticosteroid eye drops prior to and for 72 hours following each dose. Patients should also receive ocular vasoconstrictor drops prior to each infusion and cooling eye packs should be used during the infusion. Finally, lubricating eye drops should be used daily and for 30 days after the last dose of Tivdak.

### **Guidelines**

The National Comprehensive Cancer Network (NCCN) cervical cancer (version 1.2024 – September 20, 2023) clinical practice guidelines recommend Tivdak for the second-line or subsequent therapy as a single agent for local/regional recurrence, stage IVB, or distant metastatic disease.<sup>2,3</sup>

### **Safety**

Tivdak has a Boxed Warning for ocular toxicity.<sup>1</sup> Tivdak can cause changes in corneal epithelium and conjunctiva resulting in changes in vision, including severe vision loss, and corneal ulceration. Withhold, reduce the dose, or permanently discontinue Tivdak depending on the severity of ocular toxicity.

### **POLICY STATEMENT**

Prior Authorization is recommended for medical benefit coverage of Tivdak. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended

approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Tivdak as well as the monitoring required for adverse events and long-term efficacy, approval requires Tivdak to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

#### **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Tivdak is recommended in those who meet the following criteria:

#### **FDA-Approved Indication**

---

1. **Cervical Cancer.** Approve for 1 year if the patient meets the following (A, B, and C):
  - A) Patient is  $\geq$  18 years of age; AND
  - B) Patient has tried at least one chemotherapy agent; AND  
Note: Examples of chemotherapy agents include cisplatin, carboplatin, paclitaxel, topotecan.
  - C) Medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve up to 200 mg administered by intravenous infusion no more frequently than once every 3 weeks.

---

#### **CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Coverage of Tivdak is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

#### **REFERENCES**

1. Tivdak™ intravenous infusion [prescribing information]. Bothell, WA: Seagen, and Plainsboro, NJ: Genmab; July 2023.
2. The NCCN Drugs and Biologics Compendium. © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on November 6, 2023. Search term: tisotumab.
3. The NCCN Cervical Cancer Clinical Practice Guidelines in Oncology (version 1.2024 – September 20, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on November 6, 2023.

**HISTORY**

<b>Type of Revision</b>	<b>Summary of Changes</b>	<b>Review Date</b>
Annual Revision	No criteria changes.	11/09/2022
Annual Revision	No criteria changes.	11/08/2023
Aspirus P&T Review	Policy reviewed and approved by Aspirus P&T committee. Annual review process	09/16/2024